阿斯利康AstraZeneca plc (AZN) 2013年年度报告「LSE」.pdf

1、Pioneering science,life-changing medicinesAstraZeneca Annual Report and Form 20-F Information 2013We are a global,innovation-driven biopharmaceutical business.We push the boundaries of science to deliver medicines that transform the lives of people around the world.Pioneering science,life-changing m

2、edicines.This Annual Report is also available on our website, information for readers of this Annual Report For further information in relation to the inclusion ofreported performance,Core financial measures and constant exchange rate(CER)growth rates as used in this Annual Report,please refer to th

3、e Financial Review on page74.Throughout this Annual Report,growth rates are expressed at CER unless otherwise stated.Definitions The Glossary and the Market definitions table from page 232 are intended to provide a useful guide to terms and AstraZenecas definitions of markets,as well as to acronyms

4、and abbreviations,used in this Annual Report.Use of terms In this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.Cautionary statement regarding forward-looking statements A cautionary statement regarding

5、forward-looking statements and other essential information relating to this Annual Report can be found on the inside back cover.Directors Report The following sections make up the Directors Report,which has been prepared in accordance with the requirements of the Companies Act 2006:Corporate Governa

6、nce Report Audit Committee Report Development Pipeline Responsible Business Shareholder Information Corporate InformationStrategic Report The following sections make up the Strategic Report,which has been prepared in accordance with the requirements of the Companies Act 2006:AstraZeneca at a glance